1
|
Van Tilbeurgh M, Maisonnasse P, Palgen JL, Tolazzi M, Aldon Y, Dereuddre-Bosquet N, Cavarelli M, Beignon AS, Marcos-Lopez E, Gallouet AS, Gilson E, Ozorowski G, Ward AB, Bontjer I, McKay PF, Shattock RJ, Scarlatti G, Sanders RW, Le Grand R. Innate cell markers that predict anti-HIV neutralizing antibody titers in vaccinated macaques. Cell Rep Med 2022; 3:100751. [PMID: 36167072 PMCID: PMC9588994 DOI: 10.1016/j.xcrm.2022.100751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 06/09/2022] [Accepted: 09/02/2022] [Indexed: 12/01/2022]
Abstract
Given the time and resources invested in clinical trials, innovative prediction methods are needed to decrease late-stage failure in vaccine development. We identify combinations of early innate responses that predict neutralizing antibody (nAb) responses induced in HIV-Env SOSIP immunized cynomolgus macaques using various routes of vaccine injection and adjuvants. We analyze blood myeloid cells before and 24 h after each immunization by mass cytometry using a three-step clustering, and we discriminate unique vaccine signatures based on HLA-DR, CD39, CD86, CD11b, CD45, CD64, CD14, CD32, CD11c, CD123, CD4, CD16, and CADM1 surface expression. Various combinations of these markers characterize cell families positively associated with nAb production, whereas CADM1-expressing cells are negatively associated (p < 0.05). Our results demonstrate that monitoring immune signatures during early vaccine development could assist in identifying biomarkers that predict vaccine immunogenicity. HIV-Env SOSIP trimers induce neutralizing antibodies in cynomolgus macaques Vaccine-induced innate cells changes are characterized using mass cytometry Adjuvant and route of immunization influence early innate signatures in vaccinated NHP Early innate cell signatures predict neutralizing antibody levels
Collapse
Affiliation(s)
- Matthieu Van Tilbeurgh
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 92265 Fontenay-aux-Roses, France
| | - Pauline Maisonnasse
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 92265 Fontenay-aux-Roses, France
| | - Jean-Louis Palgen
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 92265 Fontenay-aux-Roses, France
| | - Monica Tolazzi
- Viral Evolution and Transmission Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, 20132 Milan, Italy
| | - Yoann Aldon
- Imperial College London, Faculty of Medicine, Department of Infectious Disease, London, UK
| | - Nathalie Dereuddre-Bosquet
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 92265 Fontenay-aux-Roses, France
| | - Mariangela Cavarelli
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 92265 Fontenay-aux-Roses, France
| | - Anne-Sophie Beignon
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 92265 Fontenay-aux-Roses, France
| | - Ernesto Marcos-Lopez
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 92265 Fontenay-aux-Roses, France
| | - Anne-Sophie Gallouet
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 92265 Fontenay-aux-Roses, France
| | - Emmanuel Gilson
- Life & Soft, 28 rue de la Redoute, 92260 Fontenay-aux-Roses, France
| | - Gabriel Ozorowski
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Andrew B Ward
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Ilja Bontjer
- Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands
| | - Paul F McKay
- Imperial College London, Faculty of Medicine, Department of Infectious Disease, London, UK
| | - Robin J Shattock
- Imperial College London, Faculty of Medicine, Department of Infectious Disease, London, UK
| | - Gabriella Scarlatti
- Viral Evolution and Transmission Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, 20132 Milan, Italy
| | - Rogier W Sanders
- Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA
| | - Roger Le Grand
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 92265 Fontenay-aux-Roses, France.
| |
Collapse
|
2
|
Feraoun Y, Palgen JL, Joly C, Tchitchek N, Marcos-Lopez E, Dereuddre-Bosquet N, Gallouet AS, Contreras V, Lévy Y, Martinon F, Le Grand R, Beignon AS. The Route of Vaccine Administration Determines Whether Blood Neutrophils Undergo Long-Term Phenotypic Modifications. Front Immunol 2022; 12:784813. [PMID: 35058925 PMCID: PMC8764446 DOI: 10.3389/fimmu.2021.784813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Accepted: 12/09/2021] [Indexed: 11/13/2022] Open
Abstract
Innate immunity modulates adaptive immunity and defines the magnitude, quality, and longevity of antigen-specific T- and B- cell immune memory. Various vaccine and administration factors influence the immune response to vaccination, including the route of vaccine delivery. We studied the dynamics of innate cell responses in blood using a preclinical model of non-human primates immunized with a live attenuated vaccinia virus, a recombinant Modified vaccinia virus Ankara (MVA) expressing a gag-pol-nef fusion of HIV-1, and mass cytometry. We previously showed that it induces a strong, early, and transient innate response, but also late phenotypic modifications of blood myeloid cells after two months when injected subcutaneously. Here, we show that the early innate effector cell responses and plasma inflammatory cytokine profiles differ between subcutaneous and intradermal vaccine injection. Additionally, we show that the intradermal administration fails to induce more highly activated/mature neutrophils long after immunization, in contrast to subcutaneous administration. Different batches of antibodies, staining protocols and generations of mass cytometers were used to generate the two datasets. Mass cytometry data were analyzed in parallel using the same analytical pipeline based on three successive clustering steps, including SPADE, and categorical heatmaps were compared using the Manhattan distance to measure the similarity between cell cluster phenotypes. Overall, we show that the vaccine per se is not sufficient for the late phenotypic modifications of innate myeloid cells, which are evocative of innate immune training. Its route of administration is also crucial, likely by influencing the early innate response, and systemic inflammation, and vaccine biodistribution.
Collapse
Affiliation(s)
- Yanis Feraoun
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France
| | - Jean-Louis Palgen
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France
| | - Candie Joly
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France
| | - Nicolas Tchitchek
- UMR_S 959, Immunology-Immunopathology-Immunotherapy (i3), Sorbonne Université and Inserm, Paris, France
| | - Ernesto Marcos-Lopez
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France
| | - Nathalie Dereuddre-Bosquet
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France
| | - Anne-Sophie Gallouet
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France
| | - Vanessa Contreras
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France
| | - Yves Lévy
- INSERM U955, Henri Mondor Hospital, University of Paris East, Créteil, France.,Vaccine Research Institute (VRI), Créteil, France
| | - Frédéric Martinon
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France
| | - Roger Le Grand
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France
| | - Anne-Sophie Beignon
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France
| |
Collapse
|
3
|
Libon C, Vandenberghe I, Marlin R, Gros W, Leonec M, Gomez-Pacheco M, Gallouet AS, Fraboul F, Mahfoudi A, Dereuddre-Bosquet N, Ferré P. Abstract 5531: K0401-020 anti-VISTA antibody monotherapy increases specific CD8 T cell response in non-human primates. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-5531] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: VISTA is a B7 family protein described as a negative checkpoint of T cell responses, both in autoimmunity and cancer murine models. K01401-020 is a novel IND enabling anti-VISTA antibody. In vitro, when incubated with human blood cells, K01401-020 stimulates NK cells, monocytes and cytokine production, contributing to T cell activation. In vivo, in non-human primates, K01401-020 notably induced dendritic cell activation (Loukili et al, AACR 2019). However, so far, no in vivo demonstration of anti-VISTA pharmacodynamic effect on T cells has been demonstrated beyond mouse models. Thus, we explored the effect of anti-VISTA antibody on CD8 T cell specific activation in non-human primates, using SIV immunization as a model.
Methods: The detection of T cell response amplification by immune-checkpoint inhibitors is very challenging in primates during standard PK or safety studies in the absence of adequate antigen stimulation. KLH is described as an immunogen in monkeys but induces mainly a humoral (IgG/IgM) and not a CD8 response, and thus cannot reveal the pharmacodynamic activity of immune-checkpoint inhibitors. Here, we explored well-described model of primate immunization that induces specifically a cellular response including CD8 (Martinon et al, Hum Gene Ther. 2009) to reveal the activity of Immune-checkpoints inhibitors.
Groups of three adult cynomolgus macaques were immunized thrice with 1mg of MultiSIVmac239 GTU-DNA, by intradermal route with electroporation. One-day after the last immunization, animals received a single intravenous injection of either vehicle, anti-PD1 antibody (pembrolizumab) or anti-VISTA antibody K01401-020. IFNγ ELISPOT assay was performed on PBMCs in the presence of either Nef RM9 peptide or Gag (peptide pool), while RM9 tetramer assay and cell subsets phenotyping were performed on whole blood.
Results: RM9 and gag-specific CD8 responses were evidenced as soon as after the second immunization in at least 2/3 animals from all groups. The third immunization reactivated CD8-specific responses in all groups. Pembrolizumab and anti-VISTA antibody clearly amplified CD8 specific responses respectively in 2/3 and 3/3 monkeys.
Conclusions: Here we show for the first time that a single anti-VISTA antibody infusion monotherapy in non-human primates potentializes specific CD8 T cell responses against exogenous antigen. The above data suggests that anti-VISTA antibody K01401-020 given as a single agent may effectively boosts CD8 T cell activity against tumor antigens.
Confidential – Pierre Fabre and CEA collaboration
Citation Format: Christine Libon, Isabelle Vandenberghe, Romain Marlin, Wesley Gros, Marco Leonec, Mario Gomez-Pacheco, Anne-Sophie Gallouet, Françoise Fraboul, Abderrahim Mahfoudi, Nathalie Dereuddre-Bosquet, Pierre Ferré. K0401-020 anti-VISTA antibody monotherapy increases specific CD8 T cell response in non-human primates [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5531.
Collapse
Affiliation(s)
| | | | - Romain Marlin
- 2CEA - IDMIT/ImVA Research Institute, Fontenay-aux-Roses, France
| | - Wesley Gros
- 2CEA - IDMIT/ImVA Research Institute, Fontenay-aux-Roses, France
| | - Marco Leonec
- 2CEA - IDMIT/ImVA Research Institute, Fontenay-aux-Roses, France
| | | | | | | | | | | | - Pierre Ferré
- 1Pierre Fabre Research Institute, Toulouse, France
| |
Collapse
|
4
|
Rodrigues-Moreira S, Moreno SG, Ghinatti G, Lewandowski D, Hoffschir F, Ferri F, Gallouet AS, Gay D, Motohashi H, Yamamoto M, Joiner MC, Gault N, Romeo PH. Low-Dose Irradiation Promotes Persistent Oxidative Stress and Decreases Self-Renewal in Hematopoietic Stem Cells. Cell Rep 2017; 20:3199-3211. [DOI: 10.1016/j.celrep.2017.09.013] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Revised: 06/21/2017] [Accepted: 09/01/2017] [Indexed: 12/12/2022] Open
|
5
|
Germain C, Guillaudeux T, Galsgaard ED, Hervouet C, Tekaya N, Gallouet AS, Fassy J, Bihl F, Poupon G, Lazzari A, Spee P, Anjuère F, Pangault C, Tarte K, Tas P, Xerri L, Braud VM. Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions. Oncoimmunology 2015; 4:e1026503. [PMID: 26405582 DOI: 10.1080/2162402x.2015.1026503] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Revised: 02/27/2015] [Accepted: 02/27/2015] [Indexed: 12/21/2022] Open
Abstract
Non-Hodgkin's lymphomas (NHLs) are malignant neoplasms which are clinically and biologically diverse. Their incidence is constantly increasing and despite treatment advances, there is a need for novel targeted therapies. Here, we identified Lectin-like transcript 1 (LLT1) as a biomarker of germinal center (GC)-derived B-cell NHLs. LLT1 identifies GC B cells in reactive tonsils and lymph nodes and its expression is maintained in B-cell NHLs which derive from GC, including Burkitt lymphoma (BL), follicular lymphoma (FL), and GC-derived diffuse large B-cell lymphoma (DLBCL). We further show that LLT1 expression by tumors dampens natural killer (NK) cell functions following interaction with its receptor CD161, uncovering a potential immune escape mechanism. Our results pinpoint LLT1 as a novel biomarker of GC-derived B-cell NHLs and as a candidate target for innovative immunotherapies.
Collapse
Affiliation(s)
- Claire Germain
- Institut de Pharmacologie Moléculaire et Cellulaire; CNRS UMR7275 ; Valbonne, France ; Université de Nice-Sophia Antipolis ; Valbonne, France ; Laboratory "Cancer, Immune control and Escape,", Cordeliers Research Center; UMRS1138 ; Paris, France
| | - Thierry Guillaudeux
- Université de Rennes 1; INSERM, Unité 917; EFS Bretagne; UMS 3480CNRS 018INSERM Biosit ; Rennes, France
| | | | - Catherine Hervouet
- Institut de Pharmacologie Moléculaire et Cellulaire; CNRS UMR7275 ; Valbonne, France ; Université de Nice-Sophia Antipolis ; Valbonne, France
| | - Nedra Tekaya
- Institut de Pharmacologie Moléculaire et Cellulaire; CNRS UMR7275 ; Valbonne, France ; Université de Nice-Sophia Antipolis ; Valbonne, France
| | - Anne-Sophie Gallouet
- Université de Rennes 1; INSERM, Unité 917; EFS Bretagne; UMS 3480CNRS 018INSERM Biosit ; Rennes, France
| | - Julien Fassy
- Institut de Pharmacologie Moléculaire et Cellulaire; CNRS UMR7275 ; Valbonne, France ; Université de Nice-Sophia Antipolis ; Valbonne, France
| | - Franck Bihl
- Institut de Pharmacologie Moléculaire et Cellulaire; CNRS UMR7275 ; Valbonne, France ; Université de Nice-Sophia Antipolis ; Valbonne, France
| | - Gwenola Poupon
- Institut de Pharmacologie Moléculaire et Cellulaire; CNRS UMR7275 ; Valbonne, France ; Université de Nice-Sophia Antipolis ; Valbonne, France
| | - Anne Lazzari
- Institut de Pharmacologie Moléculaire et Cellulaire; CNRS UMR7275 ; Valbonne, France ; Université de Nice-Sophia Antipolis ; Valbonne, France
| | - Pieter Spee
- Biopharmaceutical Research Unit, Novo Nordisk A/S , DK-2760; Måløv, Denmark
| | - Fabienne Anjuère
- Institut de Pharmacologie Moléculaire et Cellulaire; CNRS UMR7275 ; Valbonne, France ; Université de Nice-Sophia Antipolis ; Valbonne, France
| | - Céline Pangault
- Université de Rennes 1; INSERM, Unité 917, EFS Bretagne; CHU de Rennes, Service d'Hématologie, UMS 3480CNRS 018INSERM Biosit ; Rennes, France
| | - Karin Tarte
- Université de Rennes 1; INSERM, Unité 917, EFS Bretagne; CHU de Rennes, Service d'Hématologie, UMS 3480CNRS 018INSERM Biosit ; Rennes, France
| | - Patrick Tas
- Université de Rennes 1; INSERM, Unité 917, EFS Bretagne; CHU de Rennes, Service d'Hématologie, UMS 3480CNRS 018INSERM Biosit ; Rennes, France
| | - Luc Xerri
- Département d'Oncologie Moléculaire; Centre de Recherche en Cancérologie de Marseille; INSERM UMR89 , IFR137; Marseille, France
| | - Veronique M Braud
- Institut de Pharmacologie Moléculaire et Cellulaire; CNRS UMR7275 ; Valbonne, France ; Université de Nice-Sophia Antipolis ; Valbonne, France
| |
Collapse
|
6
|
Gallouet AS, Travert M, Bresson-Bepoldin L, Guilloton F, Pangault C, Caulet-Maugendre S, Lamy T, Tarte K, Guillaudeux T. COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis. Clin Cancer Res 2014; 20:2663-73. [PMID: 24637636 DOI: 10.1158/1078-0432.ccr-13-2305] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Despite therapeutic advances, non-Hodgkin lymphomas (NHL) remain incurable. They form a group of neoplasms strongly dependent on their inflammatory microenvironment, which plays an important supportive role in tumor B-cell survival and in the resistance to antitumor immune response. New therapies must consider both tumor cells and their surrounding microenvironment EXPERIMENTAL DESIGN Stromal cells, derived from bone marrow or lymph nodes, and B cells from follicular lymphoma patients were cocultured or cultured alone with celecoxib treatment, a nonsteroidal anti-inflammatory drug, and/or TRAIL, a promising cytotoxic molecule for cancer therapy. RESULTS In this study, we show that follicular lymphoma stromal cells produce large amounts of PGE2. This production is abrogated after celecoxib treatment, targeting the COX-2 isoenzyme involved in PGE2 synthesis. Furthermore, we demonstrate that celecoxib increases apoptosis in NHL B-cell lines and in primary follicular lymphoma B cells cocultured with stromal cells, but independently of the PGE2/COX-2 axis. Finally, celecoxib increases the apoptotic activity of TRAIL. We provide evidence that celecoxib affects proliferation and sensitizes NHL B-cell lines to apoptosis through COX-2-independent effects by slowing down the cell cycle and decreasing the expression of survival proteins, such as Mcl-1. CONCLUSIONS These data suggest new potent strategies for NHL therapy combining drugs targeting both tumor B cells and survival signals provided by the tumor microenvironment.
Collapse
Affiliation(s)
- Anne-Sophie Gallouet
- Authors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, France
| | - Marion Travert
- Authors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, France
| | - Laurence Bresson-Bepoldin
- Authors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, France
| | - Fabien Guilloton
- Authors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, France
| | - Céline Pangault
- Authors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, France
| | - Sylvie Caulet-Maugendre
- Authors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, France
| | - Thierry Lamy
- Authors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, France
| | - Karin Tarte
- Authors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, France
| | - Thierry Guillaudeux
- Authors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, FranceAuthors' Affiliations: INSERM, UMR 917; Université Rennes 1; EFS Bretagne; Centre Hospitalier Universitaire (CHU), Service d'Hématologie; Biosit, SFR Biologie-Santé, Rennes; INSERM, U955, Créteil; and INSERM, U916, Bordeaux, France
| |
Collapse
|
7
|
Braun F, Bertin-Ciftci J, Gallouet AS, Millour J, Juin P. Serum-nutrient starvation induces cell death mediated by Bax and Puma that is counteracted by p21 and unmasked by Bcl-x(L) inhibition. PLoS One 2011; 6:e23577. [PMID: 21887277 PMCID: PMC3160893 DOI: 10.1371/journal.pone.0023577] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2011] [Accepted: 07/20/2011] [Indexed: 01/14/2023] Open
Abstract
The cyclin-dependent kinase inhibitor p21 (p21WAF1/Cip1) is a multifunctional protein known to promote cell cycle arrest and survival in response to p53-dependent and p53 independent stimuli. We herein investigated whether and how it might contribute to the survival of cancer cells that are in low-nutrient conditions during tumour growth, by culturing isogenic human colorectal cancer cell lines (HCT116) and breast cancer cell lines in a medium deprived in amino acids and serum. We show that such starvation enhances, independently from p53, the expression of p21 and that of the pro-apoptotic BH3-only protein Puma. Under these conditions, p21 prevents Puma and its downstream effector Bax from triggering the mitochondrial apoptotic pathway. This anti-apoptotic effect is exerted from the cytosol but it is unrelated to the ability of p21 to interfere with the effector caspase 3. The survival function of p21 is, however, overcome by RNA interference mediated Bcl-x(L) depletion, or by the pharmacological inhibitor ABT-737. Thus, an insufficient supply in nutrients may not have an overt effect on cancer cell viability due to p21 induction, but it primes these cells to die, and sensitizes them to the deleterious effects of Bcl-x(L) inhibitors regardless of their p53 status.
Collapse
Affiliation(s)
- Frédérique Braun
- Institut de Recherche Thérapeutique de l'Université de Nantes, Centre de Recherche en Cancérologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale UMR 892/Université de Nantes, Nantes, France
- * E-mail: (FB); (PJ)
| | - Joséphine Bertin-Ciftci
- Institut de Recherche Thérapeutique de l'Université de Nantes, Centre de Recherche en Cancérologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale UMR 892/Université de Nantes, Nantes, France
| | - Anne-Sophie Gallouet
- Institut de Recherche Thérapeutique de l'Université de Nantes, Centre de Recherche en Cancérologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale UMR 892/Université de Nantes, Nantes, France
| | - Julie Millour
- Institut de Recherche Thérapeutique de l'Université de Nantes, Centre de Recherche en Cancérologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale UMR 892/Université de Nantes, Nantes, France
| | - Philippe Juin
- Institut de Recherche Thérapeutique de l'Université de Nantes, Centre de Recherche en Cancérologie Nantes Angers, Institut National de la Santé et de la Recherche Médicale UMR 892/Université de Nantes, Nantes, France
- * E-mail: (FB); (PJ)
| |
Collapse
|